3110-305-002 – Migraine with or without Aura in Children or Adolescents (age 6-17)

3110-305-002 Acute treatment of migraine with or without Aura in Children or Adolescents (age 6-17)

$

This study evaluates the safety and effectiveness of a new drug called ubrogepant for pediatric migraines.

$

This trial is accepting new patients.

$

The purpose of this study is to evaluate, the efficacy, safety, tolerability, and pharmacokinetics (PK) of Ubrogepant for the acute study treatment of migraine in children and adolescents.

$

Basic Enrollment Criteria:

  • Age 6-17 years old, Male & Female
  • Willing to comply with study visits and requirements
$

Study Length:

  • Main Study may last a few weeks or up to approximately 6 months.
    Pharmacokinetic Cohort Study (for children age 6-11) may last up to 3-14 days.

Participate In This Study

Sign-up Here